157 related articles for article (PubMed ID: 35201475)
1. The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study.
Ke K; Pillai K; Mekkawy AH; Akhter J; Badar S; Valle SJ; Morris DL
Discov Oncol; 2021 Aug; 12(1):25. PubMed ID: 35201475
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal BromAc
Mekkawy AH; Breakeit M; Pillai K; Badar S; Akhter J; Valle SJ; Morris DL
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444430
[TBL] [Abstract][Full Text] [Related]
3. Effective Use of Bromelain and Acetylcysteine (BromAc
Skalkos E; Chen KL; Wijayawardana R; Morris DL
Anticancer Res; 2023 Oct; 43(10):4735-4738. PubMed ID: 37772592
[TBL] [Abstract][Full Text] [Related]
4. Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei.
Lam AR; Bazzi K; Valle SJ; Morris DL
Case Rep Oncol; 2021; 14(1):628-633. PubMed ID: 33976645
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Treatment of Unresectable Pseudomyxoma Peritonei with Multiple Treatments of Intratumoural Bromelain and Acetylcysteine (BromAc
Yang J; Glenn D; Lodh S; Valle S; Morris DL
Case Rep Oncol; 2023; 16(1):1551-1556. PubMed ID: 38074518
[TBL] [Abstract][Full Text] [Related]
6. Bromelain and acetylcysteine (BromAc
Wen HK; Valle SJ; Morris DL
Am J Cancer Res; 2023; 13(4):1522-1532. PubMed ID: 37168359
[TBL] [Abstract][Full Text] [Related]
7. Bromelain and acetylcysteine (BromAc
Mekkawy AH; Pillai K; Suh H; Badar S; Akhter J; Képénékian V; Ke K; Valle SJ; Morris DL
Am J Transl Res; 2021; 13(12):13524-13539. PubMed ID: 35035694
[TBL] [Abstract][Full Text] [Related]
8. A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study.
Valle SJ; Akhter J; Mekkawy AH; Lodh S; Pillai K; Badar S; Glenn D; Power M; Liauw W; Morris DL
Eur J Surg Oncol; 2021 Jan; 47(1):115-122. PubMed ID: 31679953
[TBL] [Abstract][Full Text] [Related]
9. Effect of Nebulized BromAc on Rheology of Artificial Sputum: Relevance to Muco-Obstructive Respiratory Diseases.
Pillai K; Mekkawy AH; Akhter J; Morris DL
Adv Respir Med; 2023 Apr; 91(2):146-163. PubMed ID: 37102780
[TBL] [Abstract][Full Text] [Related]
10. Addition of bromelain and acetylcysteine to gemcitabine potentiates tumor inhibition
Mekkawy AH; Pillai K; Badar S; Akhter J; Ke K; Valle SJ; Morris DL
Am J Cancer Res; 2021; 11(5):2252-2263. PubMed ID: 34094682
[TBL] [Abstract][Full Text] [Related]
11. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Int J Cancer; 2014 Jan; 134(2):478-86. PubMed ID: 23843173
[TBL] [Abstract][Full Text] [Related]
12. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment.
Lohani K; Shetty S; Sharma P; Govindarajan V; Thomas P; Loggie B
Ann Surg Oncol; 2014 May; 21(5):1441-7. PubMed ID: 24046117
[TBL] [Abstract][Full Text] [Related]
13. A novel method for potentiation of chemotherapy in soft tissue sarcomas with BromAc.
Dong L; Ke K; Badar S; Mekkawy AH; Akhter J; Pillai K; Carter CJ; Morris DL
Am J Transl Res; 2022; 14(5):2894-2909. PubMed ID: 35702130
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
15. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
Hotta M; Minamimoto R; Gohda Y; Igari T; Yano H
Eur Radiol; 2019 Oct; 29(10):5709-5716. PubMed ID: 30874878
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma peritonei (PMP) and its therapy - 20 years experience of a single surgical department.
Bartoška P; Antoš F; Vítek P; Marx J; Holečková P; Novotný M; Kengbaeva M
Rozhl Chir; 2020; 99(4):159-166. PubMed ID: 32545978
[TBL] [Abstract][Full Text] [Related]
17. [Pseudomyxoma peritonei (PMP) secondary to mucinous carcinoma of the ovary: a case study].
Belhamidi MS; Zorkani Y; Krimou H; Kaoukabi A; Menfaa M; Sakit F; Choho K
Pan Afr Med J; 2019; 33():283. PubMed ID: 31692896
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.
Järvinen P; Ristimäki A; Kantonen J; Lepistö A
Scand J Surg; 2013; 102(3):145-51. PubMed ID: 23963027
[TBL] [Abstract][Full Text] [Related]
19. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
20. [The perioperative safety of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):419-424. PubMed ID: 32482033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
